News & Events
< Back to News Overview
ChemGenex Appoints Experienced Biotechnology Executive as Chief Medical Officer Chief Medical Officer
08 / 10 / 2007
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced the appointment of Adam R. Craig MD, PhD, MBA as Senior Vice President and Chief Medical Officer. In this position, Dr. Craig will leverage more than 15 years of clinical, oncology and drug development experience to direct ChemGenexs global clinical development strategies and to design and implement clinical trials to evaluate the companys pipeline of novel cancer therapeutic agents. Dr. Craig also will be responsible for building and leading ChemGenexs clinical development and translational medicine team.
Dr. Craig has extensive expertise in building and managing clinical teams focused on product
registration, with particular experience in developing therapies for hematologic malignancies such as chronic myeloid leukemia (CML). Most recently, he was Vice President and founding Chief Medical Officer at Innovive Pharmaceuticals, Inc., an oncology and hematology drug development company based in New York. In this position, Dr. Craig led product development activities, including preclinical development; pharmacokinetics and toxicology; regulatory affairs and clinical development. Prior to joining Innovive, Dr. Craig held positions of increasing responsibility including Vice President and Medical Director at ArQule Inc., Senior Director at Ilex Oncology Inc., and Medical Advisor at Antisoma plc. Dr. Craig received his medical qualifications from London University, a PhD in molecular medicine at the University of Leeds, and an MBA from the Open Business School, in the United Kingdom. Dr. Craig is a member of the Royal College of Physicians (UK) and undertook post-graduate training in pediatrics and pediatric oncology.
"As we position omacetaxine for regulatory submission and possible market launch, Dr. Craig is a pivotal appointment for ChemGenex. His medical expertise and entrepreneurial spirit make him an ideal member of the ChemGenex team, and we look forward to the positive impact that he will have leading our clinical development activities," said Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex. "Adam Craig has a proven track record of success in developing novel compounds, managing both early and late stage clinical development activities. In addition to guiding the completion of the registration-directed phase 2/3 clinical trails, his skills as a leader and manager will play an integral role in our plans to build ChemGenex into the future."
Dr. Craig commented, "I am delighted to join ChemGenex at this exciting stage in the companys development. I look forward to being a part of a team that shares my passion for improving the treatment options for patients with hematological and other cancers."
Dr. Craig will lead the clinical development team at ChemGenex, which has been strengthened by two other appointments in recent months. Mr. Eric Humphriss (Senior Director of Clinical Affairs) and Mr. Ed Kirk (Associate Director of Clinical Affairs) have both joined the company from Genentech, Inc. Both Mr. Humphriss and Mr. Kirk have extensive experience in drug development in the biotechnology and pharmaceutical industries, focusing on oncology clinical development programs that have resulted in successful submissions and FDA approvals.
Dr. Craig has extensive expertise in building and managing clinical teams focused on product
registration, with particular experience in developing therapies for hematologic malignancies such as chronic myeloid leukemia (CML). Most recently, he was Vice President and founding Chief Medical Officer at Innovive Pharmaceuticals, Inc., an oncology and hematology drug development company based in New York. In this position, Dr. Craig led product development activities, including preclinical development; pharmacokinetics and toxicology; regulatory affairs and clinical development. Prior to joining Innovive, Dr. Craig held positions of increasing responsibility including Vice President and Medical Director at ArQule Inc., Senior Director at Ilex Oncology Inc., and Medical Advisor at Antisoma plc. Dr. Craig received his medical qualifications from London University, a PhD in molecular medicine at the University of Leeds, and an MBA from the Open Business School, in the United Kingdom. Dr. Craig is a member of the Royal College of Physicians (UK) and undertook post-graduate training in pediatrics and pediatric oncology.
"As we position omacetaxine for regulatory submission and possible market launch, Dr. Craig is a pivotal appointment for ChemGenex. His medical expertise and entrepreneurial spirit make him an ideal member of the ChemGenex team, and we look forward to the positive impact that he will have leading our clinical development activities," said Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex. "Adam Craig has a proven track record of success in developing novel compounds, managing both early and late stage clinical development activities. In addition to guiding the completion of the registration-directed phase 2/3 clinical trails, his skills as a leader and manager will play an integral role in our plans to build ChemGenex into the future."
Dr. Craig commented, "I am delighted to join ChemGenex at this exciting stage in the companys development. I look forward to being a part of a team that shares my passion for improving the treatment options for patients with hematological and other cancers."
Dr. Craig will lead the clinical development team at ChemGenex, which has been strengthened by two other appointments in recent months. Mr. Eric Humphriss (Senior Director of Clinical Affairs) and Mr. Ed Kirk (Associate Director of Clinical Affairs) have both joined the company from Genentech, Inc. Both Mr. Humphriss and Mr. Kirk have extensive experience in drug development in the biotechnology and pharmaceutical industries, focusing on oncology clinical development programs that have resulted in successful submissions and FDA approvals.